

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>17</b>
<b>1. Basic Aspects of Pain .....</b>	<b>19</b>
<b>Introduction .....</b>	<b>19</b>
<b>Historical aspects of pain .....</b>	<b>19</b>
<b>Pain definitions .....</b>	<b>21</b>
<b>A glossary of terms relevant to pain .....</b>	<b>22</b>
<b>Pain classification and description .....</b>	<b>22</b>
Neuropathic pain.....	23
Cancer pain.....	25
<i>Bone pain in cancer.....</i>	<i>27</i>
Complex regional pain syndrome .....	27
<b>Mechanisms of pain .....</b>	<b>28</b>
Pain pathways .....	28
<i>Role of nociceptors in pain transmission.....</i>	<i>29</i>
Gate control and neuromatrix theories of pain .....	30
Pain mediators .....	31
Modulation of pain by pictures associated with social contacts .....	31
Modulation of pain by emotions .....	31
Role of the sympathetic nervous system in pain.....	32
Visceral pain.....	32
<i>Pathomechanism of visceral pain .....</i>	<i>32</i>
Pathomechanism of neuropathic pain .....	33
<i>Role of intact nerve fibers in neuropathic pain .....</i>	<i>33</i>
<i>Chemokines as mediators of neuropathic pain .....</i>	<i>33</i>
<i>Chemotherapy-induced neuropathic pain .....</i>	<i>34</i>
<i>CNS innate immunity and neuropathic pain .....</i>	<i>34</i>
<i>Cytokines as mediators of neuropathic pain.....</i>	<i>34</i>
<i>Free radicals in generation of neuropathic pain .....</i>	<i>34</i>
<i>Genetic basis of neuropathic pain.....</i>	<i>35</i>
<i>Gene expression changes in neuropathic pain.....</i>	<i>35</i>
<i>Glial activation and neuropathic pain .....</i>	<i>36</i>
<i>Immune cell-derived opioids and neuropathic pain .....</i>	<i>36</i>
<i>Spinal leptin and neuropathic pain .....</i>	<i>36</i>
<i>Tetrahydrobiopterin regulates neuropathic pain sensitivity .....</i>	<i>37</i>
Pathomechanism of migraine.....	37
Role of the immune system in pain .....	38
Pain and itch .....	38
<i>Pathomechanism of itch.....</i>	<i>38</i>
<i>Clinical aspects of itch .....</i>	<i>39</i>
Molecular pathophysiology of pain.....	39
Role of ion channels in pain.....	39
<i>Acid-sensing ion channels .....</i>	<i>40</i>
<i>Calcium channels in pain.....</i>	<i>40</i>
<i>P2X3 ion channels.....</i>	<i>41</i>
<i>Potassium ion channels.....</i>	<i>41</i>
<i>Sodium ion channels in pain.....</i>	<i>41</i>
<i>TRP ion channels in pain .....</i>	<i>43</i>
Genetic basis of pain .....	43
<i>Study of genes in pain.....</i>	<i>44</i>
<i>Pain as a channelopathy .....</i>	<i>45</i>
Pain in the brain .....	45
<i>Neuropathic pain-induced morphological changes in the brain .....</i>	<i>45</i>
Change from acute to chronic pain .....	46
<i>Descending facilitatory modulation of pain .....</i>	<i>46</i>
<i>Development of chronic pain following severe accidental injury.....</i>	<i>47</i>
<i>Pain and transcriptional repressor DREAM .....</i>	<i>47</i>
<i>Role of neuronal plasticity in pain.....</i>	<i>47</i>
Neurochemistry of pain.....	48
<i>Molecular elements of pain in the peripheral nervous system.....</i>	<i>48</i>
<i>Molecular elements of pain in the central nervous system .....</i>	<i>49</i>
<i>Opioid receptors .....</i>	<i>49</i>
<i>Role of AMPA receptors in chronic pain .....</i>	<i>49</i>
<i>Kinins.....</i>	<i>50</i>
<i>Serotonin.....</i>	<i>50</i>
<i>Substance P.....</i>	<i>50</i>
<i>Excitatory amino acids.....</i>	<i>50</i>
<i>Role of nitric oxide in pain.....</i>	<i>51</i>

<i>Prostaglandins</i> .....	51
<i>Endocannabinoids</i> .....	52
<i>Protein kinase C</i> .....	52
<i>Adenosine and adenosine receptors</i> .....	53
<i>Vitamin D and pain</i> .....	53
<i>Vanilloid receptor</i> .....	53
<i>TRPA<sub>1</sub> and TRPV<sub>1</sub> receptors</i> .....	53
<i>Endothelin-B receptors</i> .....	55
<i>Nerve growth factor and pain</i> .....	55
<i>Adrenomedullin as a pain-related peptide</i> .....	55
Biomarkers of pain .....	55
<i>Biomarkers of visceral pain</i> .....	56
<b>2. Assessment of Pain and Analgesics .....</b>	<b>58</b>
<b>Introduction .....</b>	<b>58</b>
<b>Animal models of pain .....</b>	<b>58</b>
An overview .....	58
Selection of animal species as models for pain.....	58
Types of noxious stimuli .....	59
Animal models of neuropathic pain.....	59
Animal models of arthritis .....	59
Animal models of peripheral neuropathy .....	60
Limitations of current pain models .....	60
Biogenic animal model of chronic pain .....	61
Ethical issues concerning animal pain models .....	61
<b>Medical evaluation of pain .....</b>	<b>62</b>
Chronic pain as a manifestation of various diseases .....	62
<b>Assessment of pain patients .....</b>	<b>62</b>
Medical examination.....	62
Measurement of pain.....	63
Quantitative sensory testing.....	64
Pain measurement tools for neonates and children.....	65
Quantitative sensory testing.....	65
Psychological assessment of pain .....	66
Brain imaging in pain .....	66
<i>PET for study of pain</i> .....	66
<i>PET correlated with fMRI and evoked potentials</i> .....	67
Patient outcomes and quality of life during treatment for chronic pain .....	67
Collection and analysis of data on pain patients .....	68
<b>Evaluation of analgesics in humans .....</b>	<b>68</b>
Early phase clinical trials of analgesics in humans .....	68
Design of clinical trials for pain .....	69
Assessment of neuropathic pain.....	70
Transdermal electrical stimulation for study of chronic pain.....	70
Placebo effect in pain .....	71
Role of electronic pain recording in determination of the placebo effect.....	71
Outcome measures for chronic pain trials.....	72
Pain, pain therapies and cognitive function.....	72
<b>3. Pharmacotherapy of Pain.....</b>	<b>74</b>
<b>Introduction .....</b>	<b>74</b>
<b>Mechanism of action of currently used pain medications .....</b>	<b>74</b>
<b>Non-steroidal antiinflammatory drugs .....</b>	<b>75</b>
COX-2 inhibitors .....	75
<i>Celecoxib</i> .....	76
<i>Metamizole</i> .....	77
<i>Nimesulide</i> .....	77
<i>Rofecoxib</i> .....	77
<i>Valdecoxib</i> .....	78
<i>Lumiracoxib</i> .....	78
<i>Side effects of COX inhibitors</i> .....	79
<i>Innovative COX-2 inhibitors in development</i> .....	80
Acetaminophen.....	81
<b>Antioxidants as analgesics.....</b>	<b>81</b>
<b>Opiates and opioids .....</b>	<b>82</b>
Innovations in opioid therapy .....	82
<i>Oral transmucosal fentanyl</i> .....	83
<i>Use of opioids for chronic non-cancer pain</i> .....	83
Opioid receptor modulation for visceral pain .....	83
Opiorphin.....	84
<b>N-methyl-D-aspartate receptor antagonists .....</b>	<b>84</b>

Ketamine .....	84
CNS 5161 .....	85
<b>Triptans for treatment of non-migrainous pain.....</b>	<b>85</b>
<b>Capsaicin .....</b>	<b>85</b>
NGX-4010.....	86
<b>Local anesthetics .....</b>	<b>86</b>
Topical application .....	86
Nerve blocks .....	86
<i>Injection of local anesthetics for analgesia .....</i>	<i>87</i>
<i>Ultrasound-guided nerve blocks.....</i>	<i>87</i>
<b>Topical salicylates for the treatment of pain.....</b>	<b>87</b>
<b>Topical rubefacients for acute and chronic pain in adults .....</b>	<b>87</b>
<b>Adjunctive analgesics .....</b>	<b>88</b>
Antidepressants.....	88
<i>Mechanism of analgesic action of antidepressants .....</i>	<i>89</i>
Antiepileptic drugs .....	90
<i>Mechanism of action of antiepileptic drugs in neuropathic pain.....</i>	<i>90</i>
Carbamazepine.....	91
Gabapentin .....	91
Lamotrigine.....	92
Phenytoin .....	92
Pregabalin.....	93
Topiramate .....	94
Valproic acid.....	94
<i>Other antiepileptic drugs.....</i>	<i>94</i>
<b>Clonidine.....</b>	<b>94</b>
<b>Baclofen.....</b>	<b>95</b>
<b>Corticosteroids .....</b>	<b>95</b>
<b>Calcitonin.....</b>	<b>96</b>
<b>Bisphosphonates .....</b>	<b>96</b>
<b>Botulinum toxins .....</b>	<b>96</b>
Analgesic effect of botulinum toxin A.....	97
Engineered botulinum toxin.....	97
<b>Analgesics from traditional medical systems .....</b>	<b>97</b>
Herbs and other plants .....	98
Analgesics derived from cobra toxin .....	99
<b>Adverse effects of analgesics.....</b>	<b>99</b>
Gastrointestinal adverse effects of NSAIDs.....	99
<i>Measures to reduce gastrointestinal adverse effects of NSAIDs .....</i>	<i>99</i>
Cardiovascular adverse effects of COX-2 inhibitors.....	99
Adverse effects of opioids .....	100
<i>Risk of addiction and development of tolerance.....</i>	<i>100</i>
<i>Companies developing products to deter abuse of opioids .....</i>	<i>100</i>
<i>Remoxy versus Oxycontin .....</i>	<i>101</i>
<i>Hyperalgesia associated with opioids .....</i>	<i>101</i>
<i>Respiratory depression .....</i>	<i>102</i>
<i>Opioid-associated constipation.....</i>	<i>102</i>
<i>Narcotic bowel syndrome .....</i>	<i>102</i>
Adverse effects of use of opioids in non-malignant pain .....	102
Approaches to reduce adverse effects of opioids .....	103
<i>PEGylated naloxol .....</i>	<i>103</i>
<i>Innovative approaches to modify opioid pharmacology .....</i>	<i>103</i>
<i>Regulatory aspects of opioid abuse, overdose and death.....</i>	<i>103</i>
Adverse effects of miscellaneous non-narcotic analgesics.....	104
<i>Adverse effects of immunosuppressants used for relief of pain.....</i>	<i>104</i>
<i>Adverse effects of acetaminophen .....</i>	<i>105</i>
<b>4. Management of Pain .....</b>	<b>106</b>
<b>Introduction .....</b>	<b>106</b>
<b>Sites for pain management.....</b>	<b>106</b>
Self-medication at home .....	106
Physicians' offices .....	106
Major hospitals .....	106
Pain centers .....	107
<b>Non-pharmacological approaches to pain .....</b>	<b>107</b>
Alternative medicine.....	107
<i>Acupuncture.....</i>	<i>108</i>
<i>Aromatherapy .....</i>	<i>108</i>
<i>Self-Controlled Energo Neuro Adaptive Regulation .....</i>	<i>109</i>
Behavioral therapy.....	109
<i>Cognition and pain .....</i>	<i>109</i>

<i>Control over brain activation and pain by using functional MRI</i> .....	109
<i>Thermal-grill illusion</i> .....	110
<i>Virtual reality therapy</i> .....	110
Local application of heat .....	110
Transcutaneous nerve stimulation .....	111
Transcranial magnetic stimulation .....	111
Neurosurgery for pain relief.....	111
<i>Ablative procedures on the nervous system</i> .....	112
<i>Procedures on peripheral, spinal and cranial nerves</i> .....	112
<i>Vagal nerve stimulation for control of pain</i> .....	112
<i>Neuromodulation</i> .....	112
<i>Spinal cord stimulation</i> .....	113
<i>Brain stimulation</i> .....	114
<i>Implantation of drug delivery devices</i> .....	114
<b>Management of special types of pain .....</b>	<b>114</b>
Acute pain .....	114
<i>Management of acute renal colic: NSAIDs vs. opioids</i> .....	114
<i>Combination of opioids and NSAIDs for acute pain</i> .....	115
<i>Reasons for inadequate management of acute pain</i> .....	115
Perioperative pain management.....	115
<i>Devices for delivery of analgesics in the postoperative period</i> .....	116
<i>Drug combination for perioperative pain</i> .....	117
<i>Gabapentin for reduction of postoperative pain</i> .....	117
<i>Ketamine for perioperative pain</i> .....	117
<i>Opioids for perioperative pain</i> .....	118
<i>Perioperative pain in neurosurgery</i> .....	118
<i>Prolonged duration local anesthesia</i> .....	119
<i>Concluding remarks on the management of postoperative pain</i> .....	119
Pain in the intensive care unit.....	120
Pain associated with sports and exercise .....	120
Pain associated with trauma .....	121
Chronic abdominal pain .....	121
Functional somatic syndromes .....	121
Fibromyalgia syndrome.....	122
<i>Pathomechanism of FMS</i> .....	122
<i>Management of FMS</i> .....	123
<i>New developments in pharmacotherapy of FMS</i> .....	123
Erythromelalgia .....	124
Irritable bowel syndrome .....	125
<i>Opioids for IBS</i> .....	125
<i>Tricyclic antidepressants for IBS</i> .....	126
<i>Serotonin-modulating drugs for IBS</i> .....	126
Musculoskeletal pain .....	126
Myofascial pain syndrome .....	127
Osteoarthritis .....	127
<i>Pathomechanism of osteoarthritis</i> .....	127
<i>Pain aggravates osteoarthritis by crosstalk between CNS and the joint</i> .....	128
<i>Management of osteoarthritis</i> .....	128
Rheumatoid arthritis.....	129
<i>Management of pain in rheumatoid arthritis</i> .....	130
<i>Disease modifying therapies in rheumatoid arthritis</i> .....	130
<i>Resurgence of interest in gold-based treatments for RA</i> .....	131
Backache .....	131
<i>Use of analgesics for management of back pain</i> .....	132
<i>Miscellaneous medical therapies for backache and sciatica</i> .....	133
Neck pain.....	134
Chronic pelvic pain .....	134
<i>Prostatitis</i> .....	135
Cancer pain.....	135
<i>Opioid treatment of cancer pain</i> .....	135
<i>Breakthrough and opioid-insensitive pains</i> .....	137
<i>Morphine-induced enhancement of cancer growth and its prevention</i> .....	137
<i>Methods of delivery of opioids for cancer pain</i> .....	137
<i>Implantation of drug delivery devices</i> .....	138
<i>Management of bone pain in cancer</i> .....	138
<i>Use of non-opioid analgesics for cancer pain</i> .....	139
<i>Adjuvant drugs for cancer pain</i> .....	139
<i>Radiation therapy</i> .....	140
<i>Alternative non-pharmacological methods</i> .....	140
<i>Anesthetic techniques</i> .....	140
<i>Surgical methods of cancer pain relief</i> .....	140

<i>Conclusions regarding management of cancer pain</i> .....	140
Chronic non-malignant pain .....	141
Headache.....	141
<i>Migraine</i> .....	142
<i>Management of acute migraine</i> .....	142
<i>Neurostimulation for migraine</i> .....	146
<i>Transcranial magnetic stimulation for migraine</i> .....	147
<i>Migraine prophylaxis</i> .....	147
<i>Cluster headache</i> .....	148
<i>Paroxysmal hemicrania</i> .....	148
<i>Tension headache</i> .....	148
<i>Chronic daily headache</i> .....	149
Trigeminal neuralgia.....	149
Dental pain .....	150
Neuropathic pain.....	150
<i>Pathogenesis of neuropathic pain</i> .....	150
<i>Chronobiology of neuropathic pain as guide to therapy</i> .....	151
<i>Management of neuropathic pain based on mechanism</i> .....	152
<i>Guidelines for the management of neuropathic pain</i> .....	152
<i>Pharmacotherapy of neuropathic pain</i> .....	152
<i>Evidence-based management of neuropathic pain</i> .....	155
Management of central neuropathic pain.....	155
<i>Neurosurgical approaches to central neuropathic pain</i> .....	155
<i>Management of neuropathic pain in syringomyelia</i> .....	156
<i>Neuropathic pain associated with spinal cord injury</i> .....	156
Peripheral neuropathic pain.....	157
<i>Management of postsurgical peripheral neuropathic pain</i> .....	157
<i>Management of chemotherapy-induced pain</i> .....	157
<i>Morton's neuroma</i> .....	158
<i>Management of peripheral diabetic neuropathy</i> .....	158
<i>Postherpetic neuralgia</i> .....	160
<i>Complex regional pain syndrome</i> .....	162
<i>An algorithm for the management of peripheral neuropathic pain</i> .....	163
Phantom limb pain .....	164
<i>Pathomechanism of phantom limb pain</i> .....	164
<i>Management of phantom limb pain</i> .....	164
Pain and depression .....	166
<i>Neurochemical link between pain and depression</i> .....	167
<i>Management of chronic pain and depression</i> .....	167
Miscellaneous painful conditions.....	168
<i>Burning mouth syndrome</i> .....	168
<i>Chronic unstable angina</i> .....	169
<i>Mastalgia</i> .....	169
<i>Ophthalmic pain</i> .....	169
<i>Pain in Parkinson's disease</i> .....	170
Management of chronic unexplained pain.....	170
Management of itching .....	170
<i>Topical applications for itching</i> .....	171
<i>Systemic therapies for itching</i> .....	172
<i>Non-pharmacological therapies for itch</i> .....	173
<b>Management of pain in special population groups</b> .....	<b>173</b>
Racial and ethnic differences in pain management .....	173
Pain in neonates .....	173
Management of pain in children .....	174
Management of pain in the elderly .....	174
Management of pain in women .....	176
<i>Reasons for increased pain perception in women</i> .....	176
<i>Chronic pelvic pain in women</i> .....	176
<i>Gender differences in response to analgesics</i> .....	176
<i>Considerations for pain management in women</i> .....	177
Management of pain in neurologically handicapped persons .....	177
Management of pain in the cognitively impaired elderly people .....	178
Management of pain in brain-damaged minimally conscious patients.....	178
Management of pain in the terminally ill .....	179
<b>Problems in the management of pain</b> .....	<b>179</b>
Inadequate pain management.....	179
Regulation of use of opioids.....	180
Suggestions for improvement of pain management by healthcare providers .....	180
Pain as the fifth vital sign.....	182
Management of neuropathic pain in patients refractory to first line treatment.....	182
<b>Multidisciplinary approaches to pain management</b> .....	<b>182</b>

<b>5. Drug Delivery for Pain .....</b>	<b>183</b>
<b>Introduction .....</b>	<b>183</b>
<b>Intra-articular injection for relief of joint pain.....</b>	<b>184</b>
<b>Controlled release drug delivery for pain.....</b>	<b>184</b>
Accelerating the effect of subcutaneous morphine.....	184
Controlled drug delivery at site of pain .....	184
Oral extended release opioids.....	185
<i>Extended release oral morphine.....</i>	<i>185</i>
<i>Controlled release oxycodone .....</i>	<i>186</i>
<i>Extended release oxymorphone .....</i>	<i>186</i>
<i>Oral extended release tramadol .....</i>	<i>186</i>
Extended release gabapentin.....	187
Use of nanotechnology for drug delivery for pain .....	187
<b>Non-injection methods of delivery of analgesics.....</b>	<b>187</b>
Topical applications for pain .....	188
<i>Topical local anesthetics .....</i>	<i>188</i>
<i>Topical NSAIDs.....</i>	<i>188</i>
<i>Topical and transdermal diclofenac.....</i>	<i>189</i>
<i>Topical application for postoperative pain.....</i>	<i>189</i>
Needle-free drug delivery for pain.....	190
<i>Glide SDI® solid dose injector.....</i>	<i>190</i>
<i>SUMAVEL™ DosePro™ needle-less injection .....</i>	<i>190</i>
Transdermal drug delivery for pain.....	190
<i>Relief of pain associated with minor medical procedures .....</i>	<i>190</i>
<i>Transdermal fentanyl.....</i>	<i>191</i>
<i>Transdermal ketoprofen.....</i>	<i>192</i>
<i>Transdermal nitroglycerine as an adjuvant to opioids .....</i>	<i>193</i>
<i>Transdermal buprenorphine .....</i>	<i>193</i>
<i>Transdermal trans-capsaicin.....</i>	<i>193</i>
<i>Powder Injection Systems.....</i>	<i>194</i>
Intranasal delivery of analgesics .....	194
<i>Intranasal morphine.....</i>	<i>195</i>
<i>Intranasal morphine derivatives.....</i>	<i>195</i>
<i>Intranasal fentanyl.....</i>	<i>196</i>
<i>Intranasal buprenorphine.....</i>	<i>196</i>
<i>Intranasal ketamine .....</i>	<i>196</i>
<i>Intranasal ketorolac .....</i>	<i>197</i>
<i>Nasal formulations for migraine .....</i>	<i>197</i>
Oral spray formulations for migraine .....	197
Delivery of analgesics by inhalation.....	198
Buccal transmucosal and sublingual delivery of analgesics .....	199
<i>Application for cancer pain .....</i>	<i>199</i>
<i>Application for non-cancer pain.....</i>	<i>199</i>
Pumps for drug delivery in pain .....	200
<i>Patient controlled analgesia.....</i>	<i>200</i>
<i>Postoperative pain pumps.....</i>	<i>200</i>
<i>Chronogesic (sufentanil) Pain Therapy System.....</i>	<i>201</i>
<i>Spinal pumps for delivery of analgesics.....</i>	<i>202</i>
<b>Spinal delivery of analgesics.....</b>	<b>202</b>
Epidural administration of analgesics .....	203
<i>Epidural dexamethasone.....</i>	<i>203</i>
<i>Epidural etanercept.....</i>	<i>204</i>
<i>Epidural morphine.....</i>	<i>204</i>
Intrathecal administration of analgesics .....	204
<i>Intrathecal CGX1160.....</i>	<i>204</i>
<i>Intrathecal fadolmidine.....</i>	<i>204</i>
<i>Intrathecal lidocaine.....</i>	<i>205</i>
<i>Intrathecal neostigmine .....</i>	<i>205</i>
<i>Intrathecal non-NMDA antagonists .....</i>	<i>205</i>
<i>Intrathecal prostaglandin antagonists.....</i>	<i>205</i>
<i>Intrathecal resiniferatoxin .....</i>	<i>206</i>
<i>Intrathecal ziconotide.....</i>	<i>206</i>
<i>Concluding remarks on intrathecal delivery of analgesic agents .....</i>	<i>207</i>
<b>Intracerebroventricular morphine for pain .....</b>	<b>207</b>
<b>Development of drug delivery systems for pain therapy .....</b>	<b>207</b>
Delivery of analgesics to the CNS across the blood brain barrier .....	208
Drug delivery systems in clinical trials .....	208
<b>6. Drug Development for Pain.....</b>	<b>211</b>
<b>Introduction .....</b>	<b>211</b>
<b>Drugs in development for pain.....</b>	<b>211</b>

<b>Current research goals .....</b>	<b>212</b>
The ideal analgesic.....	212
Pain R & D goals in the pharmaceutical industry .....	212
<b>Drug targets in the spinal cord .....</b>	<b>213</b>
<b>Drug targets in the brain .....</b>	<b>213</b>
<b>Molecular targets for analgesic drugs .....</b>	<b>213</b>
Activation of P2X7 receptors.....	213
Adenosine receptor agonists.....	214
Alfa2-adrenergic receptor agonists .....	214
Anti-NGF strategies .....	214
Bradykinin antagonists .....	215
Cannabinoids.....	215
<i>Cannabinoid receptor agonists</i> .....	216
<i>Cannabidiol</i> .....	217
<i>Cannabinor</i> .....	218
<i>Nabilone</i> .....	218
Capsaicin and VR1 receptor-based analgesics .....	219
<i>Vanilloid (capsaicin) receptor antagonists</i> .....	219
<i>VR1 receptor agonists</i> .....	219
CCR2 receptor blockade.....	220
Cholecystokinin antagonists .....	220
Cholinergic receptor agonists.....	220
Conotoxins as analgesics .....	221
Corticotropin-releasing factor .....	222
FAAH inhibitors.....	222
<i>PF-3845</i> .....	223
<i>URB597</i> .....	223
Free radical scavengers as analgesics .....	223
<i>Superoxide dismutase mimetics</i> .....	224
GABA analogues .....	224
<i>Subtype-selective GABAergic drugs</i> .....	224
Glial cell line-derived neurotrophic factor .....	225
Glutamate receptor antagonists .....	225
<i>NMDA receptor modulation for neuropathic pain</i> .....	225
<i>Alternatives to direct blocking of NMDA receptors</i> .....	226
<i>Glycine antagonists</i> .....	226
<i>Metabotropic glutamate receptors</i> .....	226
Histogranin-like compounds for the management of pain .....	227
Ion channels as targets for analgesic drugs .....	227
<i>Acid-sensing ion channels as drug target</i> .....	227
<i>Calcium channel blockers</i> .....	228
<i>P2X ion channel receptor antagonists</i> .....	228
<i>Sodium channel modulation</i> .....	229
Mas-related GPCR agonists.....	229
Microsomal prostaglandin E synthase inhibitors .....	230
NAALADase inhibitors .....	231
Nerve growth factor antagonists .....	231
Newer COX inhibitors .....	231
<i>COX-3 inhibitors</i> .....	232
<i>Dual cyclooxygenase/lipoxygenase inhibitors</i> .....	232
Neuropeptide receptor antagonists for improving the efficacy of opioids.....	232
Nicotinic acetylcholine receptors .....	232
<i>Mode of action of nACh/neural nicotinic receptor agonists</i> .....	233
<i>Potential of central nACh/neural nicotinic receptor agonists</i> .....	233
Nitric oxide-based analgesics.....	234
<i>Nitric oxide-releasing NSAIDs</i> .....	234
<i>Pharmacology of NO-SAIDs</i> .....	235
<i>COX-inhibiting nitric oxide donors</i> .....	235
<i>NO-donating structures to extend life cycle of existing analgesics</i> .....	236
<i>Nitric oxide mimetics</i> .....	236
<i>Neuronal nitric oxide synthase inhibitors</i> .....	236
Norepinephrine transporter inhibition .....	236
Opioid peptide receptors ligands .....	237
<i>Opioids with unique receptor characteristics</i> .....	238
<i>Buprenorphine</i> .....	238
<i>Nociceptin</i> .....	238
<i>Tapentadol</i> .....	239
Opioid analgesics acting outside the CNS .....	239
<i>Opioid analgesics acting at peripheral receptors</i> .....	239
<i>Peripherally acting mu-opioid receptor agonists</i> .....	240
<i>Targeting of opioid peptide-containing immune cells</i> .....	240

<i>Advantages of peripherally selective opioid drugs</i> .....	240
Resolvins .....	241
Somatostatin analogs .....	241
Substance P and neurokinin receptor antagonists.....	241
Substance P-Saporin .....	242
Targeting prostanoid synthesis .....	242
Tetrodotoxin based analgesics .....	243
TRPV1 antagonists .....	243
<i>TRPV1 antagonists in clinical trials</i> .....	244
<i>TRPV1-mediated entry of sodium channel blocker QX-314</i> .....	245
Tumor necrosis factor- $\alpha$ antagonists.....	245
<b>Biological therapies for pain .....</b>	<b>245</b>
<b>Cell therapy for pain .....</b>	<b>246</b>
Implantation of chromaffin cells.....	247
Role of stem cells in management of pain .....	247
Implantation of astrocytes secreting enkephalin.....	248
Cells for delivery of antinociceptive molecules .....	248
Implantation of genetically engineered cells .....	248
Cell therapy for low back pain.....	249
Cell therapy for knee pain due to degenerative disorders .....	250
Cell therapy for peripheral neuropathic pain .....	250
Concluding remarks on cell therapy for pain .....	250
<b>Gene therapy for pain .....</b>	<b>251</b>
Rationale of gene therapy for pain .....	251
<i>Gene therapy of peripheral neuropathy</i> .....	251
<i>Gene therapy targeted to neuroimmune component of chronic pain</i> .....	252
Methods of gene delivery for pain .....	252
Vectors for gene therapy of pain .....	253
<i>Vectors for endogenous analgesic production in cranial neuralgias</i> .....	253
Methods of gene delivery for pain .....	254
<i>Gene delivery by intrathecal route</i> .....	254
<i>Gene transfer to the dorsal nerve roots</i> .....	254
<i>Gene transfer by injections into the brain substance</i> .....	255
Antisense therapy for pain .....	255
RNAi-based approaches for pain therapy.....	256
Potential applications of gene therapy for management of pain.....	257
<i>Gene therapy for producing enkephalin to block pain signals</i> .....	257
<i>Gene therapy for upregulation of BMP in backache</i> .....	258
<i>Gene therapy for targeting nuclear factor-<math>\kappa</math>B</i> .....	259
<i>Gene therapy for neuropathic pain</i> .....	259
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i> .....	259
Concluding remarks about gene therapy for pain .....	259
<b>Preclinical development of pain drugs .....</b>	<b>260</b>
NGF-blocking antibody.....	261
Prostatic acid phosphatase as a novel analgesic.....	261
Preclinical development of drugs for neuropathic pain.....	261
<i>5-HT receptor agonists</i> .....	263
<i>A-803467</i> .....	263
<i>AM1241</i> .....	263
<i>Artemin/Neuroblastin</i> .....	263
<i>Capsazepine</i> .....	264
<i>Central nACh receptor agonists</i> .....	264
<i>CGP 35024</i> .....	265
<i>Drugs that suppress glial activation</i> .....	265
<i>Erythropoietin</i> .....	265
<i>NCX 8001</i> .....	266
<i>NR2B subtype NMDA receptor ligands</i> .....	266
<i>NW-1029</i> .....	266
<i>R116301</i> .....	267
<i>Targeting tumor necrosis factor</i> .....	267
Future targets for osteoarthritic pain .....	267
<b>Pain drugs in clinical trials.....</b>	<b>267</b>
Clinical trials of miscellaneous drugs for pain.....	268
<i>Alvimopan</i> .....	270
<i>Asimadoline</i> .....	270
<i>EN3202</i> .....	270
<i>Oxytrex</i> .....	270
Drugs in clinical trials for postsurgical pain .....	271
<i>Bicifadine</i> .....	272
<i>DepoMorphine</i> .....	272
Cox-2 inhibitors in clinical trials .....	273

Clinical trials of disease modifying therapies for arthritis .....	273
Drugs in clinical development for neuropathic pain .....	275
<i>Adenosine A1 agonists for neuropathic pain</i> .....	277
<i>AVP-923 (dextromethorphan + quinidine)</i> .....	278
<i>Botulinum toxin type A</i> .....	278
<i>CNV1014802</i> .....	278
<i>CPL7075</i> .....	278
<i>D-amino acid oxidase inhibitors</i> .....	279
<i>Glyx-13</i> .....	279
<i>IP-751</i> .....	279
<i>Lacosamide</i> .....	280
<i>Oxcarbazepine</i> .....	280
<i>Perampanel</i> .....	280
<i>Ralfinamide</i> .....	281
<i>Retigabine</i> .....	281
<i>SB-509</i> .....	281
<i>SCP-1</i> .....	281
<i>TC-6499</i> .....	282
<i>Tebanicline</i> .....	282
<i>Tezampanel</i> .....	282
<i>Thalidomide</i> .....	283
<i>TRO19622</i> .....	283
<i>V3381 (indantadol)</i> .....	283
<i>XP-13512</i> .....	284
<i>Zonisamide</i> .....	284
Drug discovery and development for migraine .....	284
<i>Drugs in clinical development for migraine</i> .....	285
<i>Clinical development of preventive therapies for migraine</i> .....	287
Drug development for visceral pain .....	288

## **7. Legal and regulatory issues of pain management..... 289**

<b>Pain relief as a legal right</b> .....	<b>289</b>
<b>Pain relief and the WHO</b> .....	<b>289</b>
<b>Regulatory issues</b> .....	<b>289</b>
Opioids and cannabinoids.....	289
DEA and use of opioids for pain relief in terminal care .....	289
FDA and COX-2 inhibitors.....	290
<b>Legal issues of COX-2 inhibitors</b> .....	<b>291</b>
<b>Regulatory issues of opioid safety</b> .....	<b>291</b>
Opioid misuse and regulatory agencies .....	291
FDA measures for safety of opioid use.....	291
Misuse of fentanyl.....	292

## **8. Pain Markets..... 293**

<b>Introduction</b> .....	<b>293</b>
<b>Epidemiological basis of pain markets</b> .....	<b>293</b>
Cancer.....	294
Neuropathic pain.....	294
Trigeminal neuralgia.....	294
Arthritis.....	294
Backache.....	294
Migraine.....	295
Multiple sclerosis.....	295
Irritable bowel syndrome .....	295
Chronic pelvic pain.....	295
Chronic pain due to traumatic brain injury .....	295
Postsurgical pain.....	296
<b>Economics of pain</b> .....	<b>296</b>
Pain as a driver of healthcare costs .....	296
Disability and financial loss through pain.....	297
<b>Pain markets based on painful conditions</b> .....	<b>297</b>
The cancer pain market .....	297
The arthritis pain market .....	298
Postsurgical pain market.....	298
The backache market .....	298
The headache market.....	299
Neuropathic pain market.....	299
Fibromyalgia market .....	300
<b>Pain markets based on drugs</b> .....	<b>300</b>
Opioids.....	300
Nonsteroidal antiinflammatory drugs.....	301

Transdermal pain therapeutics.....	301
Anesthesia.....	301
Antiepileptic drugs as analgesics.....	302
Other drugs.....	302
Hospital vs retail share of pain market.....	302
<i>Hospital versus retail opioid market.....</i>	<i>302</i>
Devices for pain.....	302
<b>Pain markets according to geographical areas.....</b>	<b>303</b>
<b>Cost effectiveness of various approaches.....</b>	<b>303</b>
<b>Unfulfilled R&amp;D needs in pain therapy.....</b>	<b>304</b>
Under treatment of pain.....	304
Unfulfilled needs in drug development for chronic pain.....	304
<b>Strategies for developing pain markets.....</b>	<b>305</b>
Finding alternatives to intrathecal administration for chronic pain.....	305
Development of other applications of analgesic drugs.....	305
Partnership of patients, pharmacists and companies.....	306
<b>Factors that may influence future pain markets.....</b>	<b>306</b>
Drivers of pain markets.....	306
Public surveys as indicators of impact of pain on people.....	307
Effect of regulatory reviews on markets for pain products.....	307
Novel versus older therapies for pain.....	308
<b>9. Future of Pain Therapeutics.....</b>	<b>309</b>
<b>Introduction.....</b>	<b>309</b>
<b>Advances in the understanding of pain.....</b>	<b>309</b>
Pathogenesis of chronic pain.....	309
Role of glia in neuropathic pain.....	309
Molecular and neurobiological techniques.....	310
Improved understanding of cancer pain.....	311
<b>Advances in drug discovery and development for pain.....</b>	<b>311</b>
Novel targets for drug discovery for pain.....	311
<i>PTH2 receptor.....</i>	<i>311</i>
<i>Modulators of endogenous cannabinoids.....</i>	<i>312</i>
Application of new technologies to pain therapeutics.....	312
<i>Application of nanobiotechnology to pain therapeutics.....</i>	<i>313</i>
<i>Technologies for the manufacture of analgesics.....</i>	<i>314</i>
<b>Future trends and needs in pain management.....</b>	<b>314</b>
<b>Pain management in future healthcare systems.....</b>	<b>315</b>
<b>Systems biology approach to pain.....</b>	<b>315</b>
<b>Personalized pain management.....</b>	<b>316</b>
Pharmacogenomics and pharmacogenetics of pain.....	317
Genetic mutations associated with reduced response to analgesics.....	318
Genetic mutations with loss of pain.....	318
Mechanism-specific management of pain.....	319
Preoperative testing to tailor postoperative analgesic requirements.....	319
<b>Strategies for improving pain management.....</b>	<b>319</b>
<b>10. Companies Involved in Pain Therapeutics.....</b>	<b>321</b>
<b>Introduction.....</b>	<b>321</b>
<b>Profiles of companies.....</b>	<b>321</b>
<b>Collaborations.....</b>	<b>490</b>
<b>11. References.....</b>	<b>495</b>
<b>Tables</b>	
Table 1-1: Landmarks in the history of pain therapeutics.....	20
Table 1-2: Classification of pain.....	22
Table 1-3: Classification of neuropathic pain.....	24
Table 1-4: Classification of chronic cancer pain according to cause.....	25
Table 1-5: Percentage of patients with pain according to the type of cancer.....	26
Table 1-6: Key molecular elements of pain in the peripheral nervous system.....	48
Table 1-7: Key molecular elements of pain in the central nervous system.....	49
Table 2-1: IASP guidelines for the use of animals in pain studies.....	61
Table 2-2: Chronic pain as a manifestation of other diseases.....	62
Table 2-3: Recommendations for assessing patient satisfaction with pain management.....	67
Table 3-1: Classification of some currently used pain medications according to mechanism.....	74
Table 3-2: Drugs used for the treatment of pain.....	74
Table 3-3: Selective COX-2 inhibitors in clinical use for pain.....	76
Table 3-4: Antiepileptic drugs with analgesic effect.....	90
Table 3-5: Companies with products to deter abuse of opioids.....	101

Table 4-1: Non-pharmacological approaches to management of pain .....	107
Table 4-2: Companies involved in neuromodulation therapy for pain .....	113
Table 4-3: Reasons for the inadequate management of acute pain.....	115
Table 4-4: Causes of chronic backache .....	131
Table 4-5: Management of chronic pelvic pain .....	134
Table 4-6: Management of pain in cancer .....	135
Table 4-7: Definitions of tolerance, physiological dependence, withdrawal and addiction.....	141
Table 4-8: A simplified classification of headache .....	141
Table 4-9: Various methods for the management of migraine.....	142
Table 4-10: Management of neuropathic pain based on mechanism and diagnosis .....	152
Table 4-11: Management of central neuropathic pain .....	155
Table 4-12: Current management of peripheral diabetic neuropathy .....	158
Table 4-13: Treatment strategies for postherpetic neuralgia.....	160
Table 4-14: Management of complex regional pain syndrome.....	162
Table 4-15: Methods of treating phantom limb pain .....	164
Table 4-16: Treatment of chronic unexplained pain due to central sensitization .....	170
Table 4-17: Anti-itching therapies.....	171
Table 4-18: Suggested improvements in the management of pain .....	181
Table 5-1: A classification of drug delivery methods used in management of pain.....	183
Table 5-2: Selected marketed non-injection drug delivery systems for pain .....	187
Table 5-3: Spinal administration of drugs for pain.....	202
Table 5-4: Selected drug delivery systems for pain in clinical development .....	208
Table 6-1: Classification of drugs in development for pain.....	211
Table 6-2: Preclinical studies on cannabinoid (CB2) receptor agonists as analgesics.....	216
Table 6-3: Cannabinoid receptor agonists in clinical development as analgesics.....	217
Table 6-4: NO-related therapies for pain.....	234
Table 6-5: Major opioids receptors and their ligands .....	237
Table 6-6: Strategies to counteract pain at various levels at periphery and in the CNS .....	243
Table 6-7: Types of TRPV1 antagonists.....	244
Table 6-8: TRPV1 antagonists in clinical trials.....	244
Table 6-9: Experimental gene therapy approaches for relief of pain .....	252
Table 6-10: Selected preclinical approaches to pain therapy.....	260
Table 6-11: Selected preclinical drugs for neuropathic pain .....	262
Table 6-12: Selected clinical trials of miscellaneous drugs for pain .....	268
Table 6-13: Selected clinical trials of drugs for postsurgical pain.....	271
Table 6-14: COX-2 inhibitors in clinical development.....	273
Table 6-15: Disease modifying drugs for arthritis in clinical trials .....	274
Table 6-16: Clinical trials of drugs for neuropathic pain .....	275
Table 6-17: Selected drugs in clinical development for migraine .....	285
Table 6-18: Therapeutic targets for treating visceral pain .....	288
Table 8-1: Market values for various painful conditions 2011-2021 .....	297
Table 8-2: Changes in market shares of drugs for neuropathic pain 2011-2021 .....	299
Table 8-3: Markets for pain according to therapies 2011-2021 .....	300
Table 8-4: Distribution of value of pain therapeutics in major markets 2011-2021 .....	303
Table 8-5: Distribution of value of opioids in major pain markets 2011-2021.....	303
Table 8-6: Distribution of value of NSAIDs in major pain markets 2011-2021.....	303
Table 8-7: Strategies for developing pain markets .....	305
Table 9-1: P450 isoforms in the metabolism of drugs used in the management of pain.....	317
Table 10-1: Product pipeline of Adolor Corporation .....	327
Table 10-2: Selected collaborations in the area of pain management .....	490

### **Figures**

Figure 1-1: Afferent pain pathways .....	28
Figure 1-2: Evolution of the gate control theory .....	30
Figure 1-3: The body self-neurometric.....	31
Figure 1-4: Various ligands and receptors on the peripheral terminals of nociceptive nerve fibers .....	48
Figure 1-5: Prostaglandin biosynthesis pathway .....	52
Figure 2-1: Biopsychosocial factors that interact and modulate the experience of pain.....	63
Figure 2-2: Pain intensity scales .....	64
Figure 4-1: The WHO step ladder for pain .....	136
Figure 4-2: An algorithm for the acute management of migraine .....	144
Figure 4-3: Neuroimmune activation events leading to sensitization of CNS .....	151
Figure 4-4: An algorithm for the management of peripheral neuropathic pain.....	163
Figure 4-5: Algorithm for management of patients with chronic pain and depression.....	168
Figure 5-1: Powder Injection Systems .....	194
Figure 6-1: Attributes of the ideal analgesic.....	212
Figure 6-2: Nerve targeting drug delivery system for gene therapy of pain .....	258
Figure 8-1: Unfulfilled needs in the treatment for chronic pain.....	304
Figure 9-1: Impact of new technologies on pain therapeutics .....	313
Figure 9-2: A scheme of personalized management of pain.....	316